← Evidence map

ArticleOncology letters2026

Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report.

Xuquan Jing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report. | OpenQuestion